Portfolio News
Sofinnova MD Start
Arnault Tzanck Institute in Nice, France, completes inaugural robotics surgeries with Moon Surgical's Maestro commercial system
The collaborative robotics system will be used by surgeons at the Institute's new weight loss clinic to increase efficiency in the operating room
PARIS and SAN FRANCISCO, Oct. 24, 2023 /PRNewswire/ -- The Arnault Tzanck Institute and Moon Surgical, a French-American pioneer in collaborative robotics, announced the successful completion of the first ten laparoscopic surgeries leveraging a new, commercially-ready Maestro System in Nice, France. The weight loss (bariatric) and abdominal surgery procedures were performed by Dr. Benjamin Cadière and Dr. Georges Debs, both laparoscopic surgeons, and mark the expansion of the hospital's bariatric practice, which aims to provide integrated care to patients at its new Clinique du Poids Idéale - a one-stop shop for weight loss.
Moon Surgical's Maestro System is designed to enhance surgeons during surgical procedures by providing an extra set of arms that they can use to control two additional instruments. In doing so, the Maestro System manages the instruments to provide optimal vision and access to tissue throughout the procedure, empowering the surgeon while allowing flexibility on staffing needs in the operating room.
"Integrating the Maestro robot was very instinctive and straightforward," said Dr. Benjamin Cadière, laparoscopic surgeon at the Institut Arnault-Tzanck. "It provides us with stability and precision that are difficult to match with human assistance. This allows us to focus all our attention on the surgical gesture, a definite benefit for the surgical team that will also benefit the patient."
Globally, around 580,000 people undergo bariatric surgery annually, which facilitates weight loss and can lead to improvements in obesity-related conditions like diabetes, sleep apnea, and hypertension, while abdominal procedures such as gallbladder removal (cholecystectomy) help over 2,000,000 patients annually. To serve these large patient populations, hospitals and surgeons need dependable tools that help optimize time and staff efficiency in the OR, allowing them to plan and treat more patients per day.
"Between conventional surgery and robotic-assisted surgery, which has been practiced in our establishment for over ten years, Moon Surgical's Maestro system could well represent the best of both worlds," says Michel Salvadori, CEO of the Institut Arnault Tzanck.
An initial version of the Maestro System was used successfully at Baptist Health in Jacksonville, Florida, earlier in the summer. Today's announcement shares the first use in the world of the new, commercially-ready Maestro System, which includes advanced features such as automated setup, digitized surgeon preferences, wide usability improvements, and design for reduced cost and scalable manufacturing.
About Moon Surgical
Moon Surgical, based in Paris, France, and San Francisco, California, believes the future of the operating room lies in the hands of the empowered surgeon. By equipping surgeons with complete control, renewed confidence, and technology adaptable to any situation they encounter, Moon Surgical strives to improve efficiency in operating rooms and provide better surgical care for patients. The minimalist, co-manipulation Maestro System uses tomorrow's technology to deliver these vital skills to surgeons today. For more information, visit www.moonsurgical.com
About Arnault Tzanck Institute
The Institut Arnault Tzanck in Saint Laurent du Var, just outside Nice, is a 250-bed private hospital and referral center for cardiac surgery and intensive care in the Alpes Maritimes department.
The Institute represents a particularly well-recognized Center of Excellence in thoracic and cardiovascular care, pulmonary oncology, digestive and urological diseases, as well as nephrology and hemodialysis. A number of outstanding, accredited care programs are represented here, including care for patients undergoing bariatric surgery.
Related News
Cure51 Launches NHS-Approved Study With Cambridge University Hospitals and Seven Other Leading UK Oncology Institutions to Unlock Cancer Survival Secrets
BrightHeart Secures FDA Clearance for First AI Software Revolutionizing Prenatal Fetal Heart Ultrasound Evaluations
Elicit Plant announces €45 Million Investment Round to Accelerate Global Expansion
TechBio startup Cure51 selects 10x Genomics Visium HD for new drug discovery initiative
Noema Pharma announces first patients dosed in Phase 2b study with Gemlapodect (NOE-105), a first-in-class investigational therapy for Tourette Syndrome